ZKB/CALL/ELI LILLY & CO/1000/0.01/28.03.25 Stock ZKB/CALL/ELI LILLY & CO/1000/0.01/28.03.25
Add to a list
To use this feature you must be a member
Log inSign up

ZKB/CALL/ELI LILLY & CO/1000/0.01/28.03.25 Stock

Warrant

LLYTAZ

CH1305145083

Market Closed - Swiss Exchange 11:20:00 2024-06-25 EDT
0.72 CHF +7.46% Intraday chart for ZKB/CALL/ELI LILLY & CO/1000/0.01/28.03.25
Current month+67.44%
1 month+63.64%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Chart ELI LILLY AND COMPANY
Chart ZKB/CALL/ELI LILLY & CO/1000/0.01/28.03.25

Latest news about ELI LILLY AND COMPANY

Top Midday Stories: Microsoft Hit with EU Antitrust Charges; Judge Blocks Swipe-Fee Settlement Between Visa, Mastercard and Retailers; Novo Nordisk Secures Chinese Approval for Weight-Loss Drug; Tesla, Ford Issue Recalls MT
Eli Lilly Working With OpenAI to Develop Medicines Against Drug-Resistant Pathogens DJ
Eli Lilly Teams Up With OpenAI to Develop Antimicrobials for Drug-Resistant Bacteria MT
Eli Lilly: collaboration agreement with OpenAI CF
More news

Quotes 5-day view

Date Price Change
24-06-25 0.72 +7.46%
24-06-24 0.67 +3.08%
24-06-21 0.65 -2.99%
24-06-20 0.67 +1.52%
24-06-18 0.66 +3.13%

Delayed Quote Swiss Exchange

Last update June 25, 2024 at 11:20 am

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying ELI LILLY AND COMPANY
Issuer ZKB
LLYTAZ
ISINCH1305145083
Date issued 2024-03-14
Strike 1,000 $
Maturity 2025-03-28 (276 Days)
Parity 100 : 1
Emission price 0.47 CHF
Emission volume N/A
Settlement règlement en espèces
Currency CHF

Technical Indicators

Highest since issue 0.72 CHF
Lowest since issue 0.25 CHF
Delta0.47x
Omega 5.288
Premium19.19x
Gearing11.19x
Moneyness 0.9070
Difference Strike 95.39 $
Difference Strike %+9.54%
Spread 0.01 CHF
Spread %1.37%
Theoretical value 0.7250
Implied Volatility 33.14 %
Total Loss Probability 63.76 %
Intrinsic value 0.000000
Present value 0.7250
Break even 1,081.05 CHF
Theta-0.01x
Vega0.03x
Rho0.02x

Company Profile

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
More about the company

Ratings for Eli Lilly and Company

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Eli Lilly and Company

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
904.6 USD
Average target price
860.5 USD
Spread / Average Target
-4.87%
Consensus
  1. Stock Market
  2. Warrants
  3. LLYTAZ Warrant